Evidence map›Paper›PMID 42198748›Full record

ArticleViruses2026

Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication.

Collins Oduor Owino, Balakrishnan Chakrapani Narmada, Gian Yi Lin, Pauline Poh Kim Aw, Nivrithi Ganesh, Jovi Tan Siying, Marie-Laure Plissonnier, Thangavelu Thangavelu Matan, Niranjan Shirgaonkar, Pablo Bifani and 4 more

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Collins Oduor OwinoLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.ORCID 0000-0003-2684-9996
Balakrishnan Chakrapani NarmadaLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.
Gian Yi LinExperimental Drug Development Centre, Agency for Science, Technology, and Research (A*STAR), 10 Biopolis Way, Chromos, Singapore 138670, Singapore.
Pauline Poh Kim AwLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.
Nivrithi GaneshLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.
Jovi Tan SiyingLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.
Marie-Laure PlissonnierUniversité Lyon 1, Inserm, PaThLiv, U1350, 69003 Lyon, France.ORCID 0000-0003-4879-4586
Thangavelu Thangavelu MatanExperimental Drug Development Centre, Agency for Science, Technology, and Research (A*STAR), 10 Biopolis Way, Chromos, Singapore 138670, Singapore.
Niranjan ShirgaonkarLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.
Pablo BifaniInfectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Blk MD4, Level 2, Singapore 117545, Singapore.
Massimo LevreroUniversité Lyon 1, Inserm, PaThLiv, U1350, 69003 Lyon, France.ORCID 0000-0002-4978-0875
Giridharan PeriyasamyExperimental Drug Development Centre, Agency for Science, Technology, and Research (A*STAR), 10 Biopolis Way, Chromos, Singapore 138670, Singapore.
Seng Gee LimDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block, Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore.
Ramanuj DasGuptaLaboratory of Precision Medicine and Cancer Evolution, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), 60 Biopolis St., #02-01 Genome, Singapore 138672, Singapore.

Funding

National Medical Research Council (NMRC), Singapore, Open Fund-Large Collaborative Grant OFLCG19May-0038National Research Foundation (NRF), Competitive Research Programme CRP26-2021-0062
6 · The paper itself

Abstract

BACKGROUND AND

aimsUnderstanding regulatory interactions between hepatitis B virus (HBV) and host factors is essential for the development of next generation host-directed antiviral therapies and the achievement of a functional HBV cure. Here, we investigated HBV-induced alterations in host gene expression in primary human hepatocytes (PHH) to identify host factors exploited by the virus for replication and persistence. Whole-transcriptome sequencing (WTS) of HBV-infected PHH identified host pathways with potential roles in the HBV life cycle. RNA interference-based functional screening of dysregulated candidate genes identified cyclin L1 (CCNL1) as a key host factor. RNAi-mediated knockdown of CCNL1 reduced HBV gene expression, including hepatitis B surface antigen (HBsAg). Mechanistically, CCNL1 regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (RNAPII) at serine 2 (S2), consistent with a role in transcriptional regulation. CCNL1 knockdown further reduced the binding of total and phospho- (Ser2/Ser5) RNAPII, pan-acetylated histone H3 (H3ac), and H3K27ac to HBV covalently closed circular DNA (cccDNA), indicating impaired cccDNA-dependent transcription. In addition, CCNL1 expression was elevated in chronic hepatitis B patients compared with those with resolved infection. Collectively, these data demonstrate that CCNL1 promotes HBV transcription and replication through modulation of RNAPII phosphorylation and chromatin-associated transcriptional activity, identifying CCNL1 as a potential host susceptibility factor for HBV. IMPORTANCE: Hepatitis B virus infection remains a major threat to human health in areas with high prevalence. There is need to fully understand the complex interactions between the virus and human host factors/processes to support ongoing efforts to develop anti-HBV therapies that can be used with existing therapies to achieve a better cure. HBV relies on host cellular factors and biological processes to establish and maintain efficient infection, making host-virus interactions attractive targets for therapeutic intervention. Thus, identifying host factors that support and/or restrict HBV infection is essential for understanding the molecular basis of chronic HBV infection and for developing host-targeting anti-HBV drugs. This study identifies cyclin L1 (CCNL1) as a host susceptibility factor that promotes HBV transcription and replication through regulation of RNA polymerase II activity and or post-transcriptional mechanisms.

Indexed as

Hepatitis BHepatitis B virusHost-Pathogen InteractionsVirus ReplicationCells, CulturedDNA, ViralHepatocytesHumansPhosphorylationRNA Polymerase IIDNA, ViralRNA Polymerase IIcccDNACCNL1HBVtranscriptionwhole transcriptome sequencing

Identifiers

PMID42198748
PMCPMC13211425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.